The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Battling Malaria: Strengthening the U.S. Military Malaria Vaccine Program
CI: 22–47 percent). It was encouraging that RTS,S also showed significant protection against severe malaria in children, estimated at 58 percent (95 percent CI: 16–81 percent) in the first six months and 49 percent (95 percent CI: 12–71 percent) over an 18 month period (Alonso et al., 2004, 2005). No significant safety issue associated with RTS,S vaccines was found, although the frequency of some local and systemic adverse effects (e.g., injection site pain, malaise) was increased compared to placebo (Bojang et al., 2005). Protection was not limited to the CSP variants used to make the vaccine (Alloueche et al., 2003).